In May 2023 the India National Anti-Doping Agency (INADA) reported an anti-doping rule violation against the powerlifter Mumin Khan after his sample tested positive for the prohibited substance Furosemide.
Following notification the Athlete filed a statement in his defence and he was heard for the Anti-Doping Disciplinary Panel of India (ADDPI).
The Athlete explained that was his first Doping Control and that he has used medication prescribed by his doctor as treatment for his high blood pressure. He asserted that he was unaware that the medication Lasix contained a prohibited substance, nor that he had to apply for a TUE.
INADA disputed the authenticity of the medical documents provided by the Athlete. Further it contended that he failed to mention his medication on the Doping Control Form, nor made an application for a TUE.
The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation.
The Panel deems that the Athlete failed to demonstrate that the violation was not intentional, nor the source of the prohibited substance. The Panel agrees that the Athlete's medical documents are dubious.
Therefore the Panel decides on 17 October 2023 to impose a 2 year period of ineligibility on the Athlete, starting on the date of the decision.
